Skip to content

Study · Not a test of the peptide alone · 2018

8 results

Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.

Yamamoto S, Hayashi T, Ohara M, Goto S, Sato J, Nagaike H, Fukase A, Sato N, Hiromura M, Tomoyasu M, Nakanishi N, Lee S and 4 more

Show all authors

Osamura A, Yamamoto T, Fukui T, Hirano T

Diabetes research and clinical practice26 Mar 2018Cited by 10 (Europe PMC)

PMID29588170 (opens in a new tab)DOI10.1016/j.diabres.2018.03.032 (opens in a new tab)PepBankPUB-29588170
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes without severe insulin deficiency, a regimen of liraglutide plus basal insulin reduced HbA1c, whereas basal-bolus insulin therapy showed no change.

    In plain wordsIn adults with type 2 diabetes, liraglutide plus basal insulin lowered HbA1c, while basal-bolus insulin did not change it.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The Lira-basal group demonstrated reduced HbA1c, whereas the BBIT group showed no change.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes without severe insulin deficiency, body weight fell with liraglutide plus basal insulin but rose with basal-bolus insulin therapy.

    In plain wordsWeight fell with liraglutide plus basal insulin but rose with basal-bolus insulin in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    BW was reduced in the Lira-basal group but increased in the BBIT group.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide plus basal insulin significantly reduced pre-breakfast self-monitored blood glucose.

    In plain wordsLiraglutide plus basal insulin lowered blood glucose before breakfast in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreasePre-breakfast self-monitored blood glucose
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The Lira-basal group also exhibited significantly reduced pre-breakfast and pre-lunch SMBG.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide plus basal insulin significantly reduced pre-lunch self-monitored blood glucose.

    In plain wordsLiraglutide plus basal insulin lowered blood glucose before lunch in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreasePre-lunch self-monitored blood glucose
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The Lira-basal group also exhibited significantly reduced pre-breakfast and pre-lunch SMBG.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, treatment satisfaction scores improved with liraglutide plus basal insulin but not with basal-bolus insulin therapy.

    In plain wordsTreatment satisfaction improved with liraglutide plus basal insulin but not with basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiabetes Treatment Satisfaction Questionnaire (DTSQs) score
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Metabolic and weight

    Source sentences

    Summary
    DTSQs scores improved in the Lira-basal group but not the BBIT group.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, plasma lipids did not change significantly in either the liraglutide plus basal insulin group or the basal-bolus group.

    In plain wordsBlood fats did not change significantly in either group.

    Peptide
    Liraglutide
    Outcome
    No significant changePlasma lipids
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Plasma lipids, liver function, and kidney function were not significantly changed in either group.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, liver function did not change significantly in either the liraglutide plus basal insulin group or the basal-bolus group.

    In plain wordsLiver function did not change significantly in either group.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver function
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Plasma lipids, liver function, and kidney function were not significantly changed in either group.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, kidney function did not change significantly in either the liraglutide plus basal insulin group or the basal-bolus group.

    In plain wordsKidney function did not change significantly in either group.

    Peptide
    Liraglutide
    Outcome
    No significant changeKidney function
    Study

    n = 25

    Comparator
    Basal-bolus insulin therapy (BBIT)
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Plasma lipids, liver function, and kidney function were not significantly changed in either group.
    2 context sentences
    Summary · context
    Fifty patients receiving BBIT were enrolled in this 24-week, prospective, randomized, open-labeled study.
    Summary · context
    After excluding subjects with fasting C-peptide immunoreactivity (CPR) < 1.0 ng/mL and CPR increase < 1.0 ng/mL at 6 min post glucagon injection, 25 were randomly allocated to receive Lira-basal (n = 12) or continued BBIT (n = 13).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.